Drug Profile
Research programme: insulin analogues - Sanofi/Theramalin
Latest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator Case Western Reserve University School of Medicine
- Developer Sanofi; Thermalin
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA (PO)
- 28 Oct 2021 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA (SC)
- 28 Oct 2021 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA (Transdermal)